182 related articles for article (PubMed ID: 37941728)
1. Combination of sacubitril/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome.
Tsukamoto S; Wakui H; Uehara T; Shiba Y; Azushima K; Abe E; Tanaka S; Taguchi S; Hirota K; Urate S; Suzuki T; Yamada T; Kinguchi S; Yamashita A; Tamura K
Eur Heart J Open; 2023 Nov; 3(6):oead098. PubMed ID: 37941728
[TBL] [Abstract][Full Text] [Related]
2. Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.
Tsukamoto S; Uehara T; Azushima K; Wakui H; Tamura K
J Am Heart Assoc; 2023 Apr; 12(8):e029565. PubMed ID: 37066800
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
4. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Kario K
Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
Codina P; Domingo M; Barceló E; Gastelurrutia P; Casquete D; Vila J; Abdul-Jawad Altisent O; Spitaleri G; Cediel G; Santiago-Vacas E; Zamora E; Ruiz-Cueto M; Santesmases J; de la Espriella R; Pascual-Figal DA; Nuñez J; Lupón J; Bayes-Genis A
ESC Heart Fail; 2022 Aug; 9(4):2170-2180. PubMed ID: 35588235
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
[TBL] [Abstract][Full Text] [Related]
8. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.
Bhat TS; Hafeez I; Tak SF; Mattoo A; Patigaroo AR; Khan A; Lone AA; Beig JR
Indian Heart J; 2022; 74(3):178-181. PubMed ID: 35483448
[TBL] [Abstract][Full Text] [Related]
10. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol.
Lee V; Zheng Q; Toh DF; Pua CJ; Bryant JA; Lee CH; Cook SA; Butler J; Díez J; Richards AM; Le TT; Chin CWL
Front Cardiovasc Med; 2023; 10():1248468. PubMed ID: 37674806
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
[TBL] [Abstract][Full Text] [Related]
14. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia.
Tsai YN; Cheng WH; Chang YT; Hsiao YW; Chang TY; Hsieh YC; Lin YJ; Lo LW; Chao TF; Kuo MJ; Higa S; Chang SL; Chen SA
J Cardiol; 2021 Oct; 78(4):275-284. PubMed ID: 34059408
[TBL] [Abstract][Full Text] [Related]
16. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
[TBL] [Abstract][Full Text] [Related]
17. Combining Neprilysin Inhibitor With AT
Gray EA; Patel SN; Doris PA; Hussain T
Front Pharmacol; 2021; 12():778953. PubMed ID: 35197849
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.
Rattanavipanon W; Sotananusak T; Yamaae F; Chandrsawang A; Kaewkan P; Nathisuwan S; Yingchoncharoen T
BMC Cardiovasc Disord; 2021 Jul; 21(1):324. PubMed ID: 34215190
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
